Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

This publication has 34 references indexed in Scilit:

• Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
  JAMA, 2011
• Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review
  Clinical Therapeutics, 2011
• Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
  New England Journal of Medicine, 2010
• Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
  Arthritis & Rheumatism, 2009
• Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease
  Gut, 2007
• Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
  Gastroenterology, 2007
• Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
  New England Journal of Medicine, 2005
• The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trial
  Arthritis & Rheumatism, 2002
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
  The Lancet, 2002
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
  Journal of Clinical Epidemiology, 1992